The Pharma Data

JULY 29, 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Small Molecule

Drug Target Review

OCTOBER 11, 2023

In those with CMT1A, over-production of a protein called PMP22 damages the nerves that supply the arms, hands, legs and feet, leading to muscle weakness or paralysis, problems with balance and loss of sensation. Autophagy boosters, in contrast, are conventional small molecule drugs.

Disease

LifeSciVC

JANUARY 16, 2024

Rise of the best-in-class biologics plays: Are you looking to in-license or invest in “de-risked” biology that is already in the clinic? The past year has seen an explosion in “fast follower” approaches to improve on existing target product profiles for select mechanisms, and was exceptionally apparent for antibodies and other biologics.

Small Molecule

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. Vlad Coric , M.D.,

Small Molecule

The Pharma Data

NOVEMBER 19, 2020

The Company is also aiming to leverage the highly conserved structure of the SARS-CoV-2 M pro protease as a basis for the design of novel oral small molecules against predicted future variants of SARS-CoV-2 and other related human viruses.

Small Molecule

The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. Global regulatory agencies, including the U.S. ICH Q3A and ICH Q3B outline expectations for reporting, identifying, and qualifying (i.e.,

Small Molecule

Fierce BioTech

AUGUST 25, 2023

In this webinar, Alcami experts will share their experience in partnering with biopharma clients to meet their specific project needs, be it early phase clinical development or late phase or commercial products, small molecules, biologics or advanced modalities.

Small Molecule

The Pharma Data

JANUARY 13, 2021

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma.

Trials

Nvidia Developer: Drug Discovery

MARCH 21, 2023

New supercomputing-scale large language models (LLMs) that understand biology and chemistry text are helping scientists understand proteins, small molecules, DNA, and biomedical text. These state-of-the-art AI models help generate de novo proteins and molecules and predict the 3D structures of proteins.

Small Molecule

The Premier Consulting Blog

JULY 31, 2024

In this blog, we explain the role of clinical pharmacology in drug development and demonstrate how the right strategy can accelerate development under the US Food and Drug Administration (FDA) 505(b)(1) and 505(b)(2) New Drug Application (NDA) pathways. and reduce the overall clinical pharmacology program.

Clinical Pharmacology

The Pharma Data

DECEMBER 10, 2020

executive vice president of research and development. “We We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”. About LX9211.

FDA

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. Xofigo is currently under further evaluation in a broad clinical development program in prostate cancer and beyond.

Small Molecule

The Pharma Data

MAY 31, 2022

We look forward to continuing our collaboration with Biogen and the Parkinson’s community in our unified goal to develop BIIB122 as a potential treatment option for people and families living with Parkinson’s disease.”. BIIB122 is an investigational small molecule inhibitor of LRRK2 that was discovered and developed by Denali.

Disease

The Pharma Data

OCTOBER 14, 2020

As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis.

Pharmaceuticals

The Pharma Data

APRIL 6, 2021

The new data reaffirm Bayer’s continued efforts to demonstrate the clinical impact a precision medicine approach can have on patients. While local labels might differ, the product is approved for adult and pediatric patients with solid tumors that harbor a NTRK gene fusion and have no satisfactory alternative treatments.

Research

The Pharma Data

SEPTEMBER 25, 2020

Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. ICR and Cancer Research UK spinout closes Series B financing. Source link.

Targeted Protein Degradation

The Pharma Data

DECEMBER 17, 2020

He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

Small Molecule

The Pharma Data

FEBRUARY 21, 2022

We are excited to see our efforts crystalize in our latest product launches, which include two potential blockbusters, as well as a late-stage portfolio with at least another blockbuster opportunity.”. Bayer is committed to drive sustainable development and generate a positive impact with its businesses.

Clinical Trials

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation

The Pharma Data

JANUARY 10, 2021

(Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, today announced it has submitted an Investigational New Drug (IND) application with the U.S. Chief Scientific Officer, IDEAYA Biosciences.

FDA

The Pharma Data

JANUARY 7, 2021

Galecto has an exciting pipeline of product candidates within fibrosis and cancer and a lead candidate in phase 2 for Idiopathic pulmonary fibrosis (IPF). Before that, Dr. Prener was Global Therapeutic Area Head of Hematology and Vice President, Clinical Research Hematology at Baxalta. a gene therapy company focused on eye diseases.

Small Molecule

The Pharma Data

JANUARY 19, 2021

Other products include SY-2101, a novel oral form of arsenic trioxide for acute promyelocytic leukemia, and SY-5609, a highly selective and potent oral CDK7 inhibitor for solid tumors. Ortho Clinical Diagnostics Holdings – Ortho launched its IPO of ordinary shares on January 19. This is planned to raise about $25 million.

Small Molecule

The Pharma Data

NOVEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Small Molecule

The Pharma Data

MARCH 1, 2022

” The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies.

Small Molecule

The Pharma Data

OCTOBER 26, 2020

The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive Staphylococcus aureus ( S.

Pharmaceuticals

The Pharma Data

JANUARY 10, 2021

10, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, will provide an update on Vision 3×3 and the company’s 2021 key milestones at the 39 th Annual J.P. COPENHAGEN, Denmark, Jan.

Clinical Trials

The Pharma Data

JANUARY 3, 2021

The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release.

Trials

Alta Sciences

APRIL 17, 2024

Our preclinical and bioanalytical experts have extensive experience in leading-edge technologies to support sponsors in the advancement of their gene therapy products. Gene Therapy resources Watch our on-demand webinar, “ Nonclinical Safety Assessment for Gene Therapy Products ”. Asia, and Europe.

Drug Development

The Pharma Data

OCTOBER 14, 2020

Horsepox-based vaccines are designed to be single dose, vial-sparing vaccines, which can be manufactured on conventional cell culturing systems, with the potential for mass scale production. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. 1 Noyce RS, et al. 2018) PLoS One.

Vaccine

The Pharma Data

JANUARY 19, 2021

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression.

Small Molecule

Precision for Medicine

JUNE 26, 2023

“Our partnerships are with the most innovative organizations, utilizing the most advanced, cutting-edge technologies and providing us with unparalleled experience in manufacturing small molecule, biologics and next-generation medicines,” said John Khoury, Executive Vice President at Project Farma.

Science

The Pharma Data

OCTOBER 14, 2020

VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications.

Treatment

The Pharma Data

AUGUST 29, 2020

3,4 LNP023 is currently in clinical development for PNH and a number of renal conditions with complement system involvement where significant unmet needs exist, including IgA nephropathy, complement 3 glomerulopathy (C3G), atypical hemolytic uremic syndrome and membranous nephropathy. Blood 2019;134(Suppl 1):3517.

Treatment

The Pharma Data

OCTOBER 18, 2020

CG-806 is an oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor and is in Phase 1 clinical studies for the treatment of lymphoid and myeloid hematologic malignancies. This press release contains forward-looking statements within the meaning of Canadian and U.S.

Clinical Trials

The Pharma Data

DECEMBER 15, 2020

Anokion is responsible for preclinical activities and Phase I clinical development of partnered programs, and Bristol Myers Squibb will fund subsequent trials and commercial activities at clinical proof-of-concept. Small Molecule Inhibitors. Oral, Small Molecules. Anti-CD40L Antibody.

Disease

The Pharma Data

NOVEMBER 8, 2020

Core EBITDA however showed underlying resilience and growth based on strong product performance. Investment in Research & Development remained at c. All Almirall’s production sites continue to operate at full capacity in order to be able to ensure the supply of medicines to all patients requiring treatment.

Licensing

The Pharma Data

JANUARY 17, 2021

“This result provides a foundation for a clinical development program using higher doses of setanaxib across a variety of orphan indications. Genkyotex’s discovery platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes.

Trials